Fluoxetine Does Not Enhance Visual Perceptual Learning and Triazolam Specifically Impairs Learning Transfer

Abstract

The selective serotonin reuptake inhibitor fluoxetine significantly enhances adult visual cortex plasticity within the rat. This effect is related to decreased gamma-aminobutyric acid (GABA) mediated inhibition and identifies fluoxetine as a potential agent for enhancing plasticity in the adult human brain. We tested the hypothesis that fluoxetine would enhance visual perceptual learning of a motion direction discrimination (MDD) task in humans. We also investigated (1) the effect of fluoxetine on visual and motor cortex excitability and (2) the impact of increased GABA mediated inhibition following a single dose of triazolam on post-training MDD task performance. Within a double blind, placebo controlled design, 20 healthy adult participants completed a 19-day course of fluoxetine (n = 10, 20 mg per day) or placebo (n = 10). Participants were trained on the MDD task over the final 5 days of fluoxetine administration. Accuracy for the trained MDD stimulus and an untrained MDD stimulus configuration was assessed before and after training, after triazolam and 1 week after triazolam. Motor and visual cortex excitability were measured using transcranial magnetic stimulation. Fluoxetine did not enhance the magnitude or rate of perceptual learning and full transfer of learning to the untrained stimulus was observed for both groups. After training was complete, trazolam had no effect on trained task performance but significantly impaired untrained task performance. No consistent effects of fluoxetine on cortical excitability were observed. The results do not support the hypothesis that fluoxetine can enhance learning in humans. However, the specific effect of triazolam on MDD task performance for the untrained stimulus suggests that learning and learning transfer rely on dissociable neural mechanisms.

Fluoxetine does not enhance the effect of perceptual learning on visual function in adults with amblyopia

“…Furthermore, there are no prior reports of visual benefits from fluoxetine monotherapy in amblyopic patients, even though millions of patients, and presumably thousands of amblyopic patients, have used the medication over the past three decades. In addition, a recent placebo-controlled, double-blinded clinical study showed that 20 mg/day of fluoxetine for 19 days did not significantly affect visual perceptual learning in humans 40 . These prior studies support the theory that 20 mg/day of fluoxetine may not be a large enough dose to effectively modulate visual cortex plasticity in adult humans.…”

Learning to see again: biological constraints on cortical plasticity and the implications for sight restoration technologies

“…In adult animal models fluoxetine results in reduced GABAergic inhibition and increased BDNF expression, which results in reopening of the critical period (Maya-Vetencourt et al 2008, Bachatene et al 2013), but a study in humans did not find that fluoxetine enhanced perceptual learning (Lagas et al 2016). In humans the FDA-approved cholinesterase inhibitor donepezil seems to enhance perceptual learning, perhaps by shifting the excitation/inhibition balance towards the ‘immature’ state of greater excitation (Rokem et al 2010, Rokem and Silver 2013, Chamoun et al 2017).…”

Effect of fluoxetine on adult amblyopia: a placebo-controlled study combining neuroplasticity-enhancing pharmacological intervention and perceptual training

“…In addition, a recent placebo-controlled, double-blinded, clinical study showed that 20 mg/day of fluoxetine for 19 days did not significantly affect visual perceptual learning in humans. 43 These prior studies support the theory that 20 mg/day of fluoxetine may not be a large enough dose to effectively modulate visual cortex plasticity in adult humans.…”